<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920396</url>
  </required_header>
  <id_info>
    <org_study_id>Eeye03182021</org_study_id>
    <nct_id>NCT04920396</nct_id>
  </id_info>
  <brief_title>Intense Regulated Pulsed Light Vs Standard of Care for the Treatment of Meibomian Gland Dysfunction</brief_title>
  <official_title>Intense Regulated Pulsed Light Vs Standard of Care for the Treatment of Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the effectiveness of E&gt;EYE intense regulated pulsed light (IRPL)&#xD;
      treatment compared to the current standard of care using a daily warm compress&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      E-Eye is a medical device that has been specifically designed for treating dry eye syndrome&#xD;
      due to meibomian gland dysfunction (MGD). This study is a prospective, single centred,&#xD;
      interventional, randomized study assessing the efficacy and safety of E&gt;EYE in the management&#xD;
      of MGD (3 applications on days 0, 15 and 45, with a follow up 1 month later) compared to&#xD;
      daily use of a warm compress over a period of 75 days.&#xD;
&#xD;
      The study will monitor the change in symptoms and signs of dry eye at each visit.)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized allocation between treatments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Ocular assessment will be undertaken by a researcher masked to the participants treatment allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms of dry eye disease</measure>
    <time_frame>Change between baseline and day 75</time_frame>
    <description>Change in Ocular Surface Disease Index (OSDI) questionnaire score from baseline to end of trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear film stability</measure>
    <time_frame>Change between baseline and day 75</time_frame>
    <description>Change in non-invasive assessed tear film retention time from baseline to end of trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eye redness</measure>
    <time_frame>Change between baseline and day 75</time_frame>
    <description>Change in ocular redness graded against standardised Efron grading scale (from 0 to 4, where lower is better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meibomian gland patency</measure>
    <time_frame>Change between baseline and day 75</time_frame>
    <description>Change in the number of glands expressing multiplied by the quality (on a 4 point standardised scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear volume</measure>
    <time_frame>Change between baseline and day 75</time_frame>
    <description>Change in tear meniscus height measured in millimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid layer thickness</measure>
    <time_frame>Change between baseline and day 75</time_frame>
    <description>Change in white light interferometry pattern graded against the Guillon standardised categories (Open meshwork, closed meshwork, wave pattern, amorphous or colored fringes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>IRPL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatments with IRPL (manufacturer: E-Swin, France) on days 0, 15 and 45</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warm compress</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily use of a warm compress (manufacturer: The Eye Doctor, UK) with Sterileyes® twice a day for 5 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>E&gt;Eye IRPL</intervention_name>
    <description>Regulated intense pulsed light therapy</description>
    <arm_group_label>IRPL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Warm compress</intervention_name>
    <description>Fabric mask with anti-bacterial coating filled with BodyBeads® heated in a microwave for 30 seconds before application over the eyes for 5 minutes</description>
    <arm_group_label>Warm compress</arm_group_label>
    <other_name>The Eye Doctor Mask</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide informed consent and participate in the required study&#xD;
             visit&#xD;
&#xD;
          -  Subjects determined to have signs and symptoms of evaporative Dry Eye disease due to&#xD;
             MGD, defined by the following:&#xD;
&#xD;
               -  OSDI score &gt;13 and&#xD;
&#xD;
               -  NITBUT &lt;= 10sec&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No use of warm compresses, intense pulsed light therapy or other lid warming treatment&#xD;
             in the past 6 Months&#xD;
&#xD;
          -  Patients with greater 75% meibomian gland loss&#xD;
&#xD;
          -  Presence of ocular pathology or systemic conditions other than previously diagnosed&#xD;
             moderate or severe chronic dry eye and/or Sjogren's syndrome, that in the&#xD;
             investigator's judgment may affect the testing for, or diagnosis of, dry eye if&#xD;
             present&#xD;
&#xD;
          -  Use of prescribed ocular topical medication (e.g., anti-hypertensive, steroid,&#xD;
             Cyclosporin A, antibiotic) within the last 24 hours&#xD;
&#xD;
          -  Artificial tear usage within 2 hours prior to study testing&#xD;
&#xD;
          -  Other invasive ocular diagnostic testing within 2 hours prior to study testing&#xD;
&#xD;
          -  Eye makeup present on the eye lid within 10 minutes prior to study testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Wolffsohn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aston University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Wolffsohn, PhD</last_name>
    <phone>07833049245</phone>
    <email>j.s.w.wolffsohn@aston.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Market Mall Eye Clinic - Calgary, AB</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>AB T3A 0E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saleel Jivraj, PhD</last_name>
      <phone>+1 587-324-2824</phone>
      <email>jivrajs1@aston.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aston University</investigator_affiliation>
    <investigator_full_name>James Wolffsohn</investigator_full_name>
    <investigator_title>associate Pro-Vice Chancellor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

